CRISPR QC

THE CRISPR ANALYTICS PLATFORM

Data for optimized gene editing



Having trouble achieving consistent high-quality CRISPR edits?

Here at CRISPR QC, we're familiar with the headache that comes with troubleshooting gene editing outcomes.


With so many potential factors affecting editing success and no good means to assess them, pinpointing the source of variation in your edits can seem like a daunting task. Current techniques such as cell assays and NGS are of little help, as they are limited to assessing the end result of an edit.

CRISPR Analytics platform — process

- 1 Contact our science team
- 2 Send us your reagents
- 3 CRISPR Analytics Platform simulates editing
- 4 Data + report containing findings sent to you
- 5 Simplified, streamlined editing workflow

Gain insight to key factors driving editing success

Powered by our patent-protected **CRISPR-CHIP™**, our **CRISPR Analytics Platform** simulates gene editing in real time, providing unique biophysical insights to optimize editing outcomes.





Reach your milestones

Quit missing milestones because results didn't match modeling predictions



Shorten R&D cycles

Better data gives your R&D team the tools it needs to do more in less time



Quality control

Ensure that your reagents are delivering consistent results

LET'S WORK TOGETHER

Get in touch to discuss how our data and collaborative approach can optimize your CRISPR editing programs



858.285.4122




kdickerson@crisprqc.com



8949 Kenamar Dr. Suite 101 San Diego, CA 92121

Optimize your CRISPR editing



The CRISPR Analytics Platform




Saving customer weeks with better gRNA selection

Problem: Established *in silico* gRNA selection models failed to accurately predict outcomes, costing customer months of lost work

Customer solution: CRISPR QC identified the highest-performing gRNAs using our unique activity data, enabling them to achieve their desired edit

Optimized editing workflows



NIST collaboration: Establishing CRISPR measurement standards

Problem: Lack of standards and consistent methods plague the CRISPR therapeutic industry; FDA + NIST working to build measurements + standards to lift industry + protect patients

Study: CRISPR QC and NIST collecting data that is demonstrating CRISPR QC measurements can select high-performing gene editing materials; study in final stages

